Browse studies
Find your next paid study
3 recruiting studies matching your filters
Phase 1
An Open-label, Multi-center, Phase I/Ib Study of IEV407 as a Single Agent and in Combination With Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2- Negative Breast Cancer
The purpose of this study is to evaluate the safety, tolerability and preliminary activity of IEV407 as a single agent and in combination with endocrine therap…
Advanced HR+/HER2- Breast Cancer
Estimated
~$10 – $8,750
Novartis PharmaceuticalsNCT07604571
Phase 1
An Open-label, Multi-center, Phase I/II Study of GVV858 as a Single Agent and in Combination With Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2- Negative Breast Cancer and Other Advanced Solid Tumors
Phase I: Characterize safety and tolerability of GVV858 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimizatio…
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer
Estimated
~$10 – $8,750
Novartis PharmaceuticalsNCT07288359
Phase 1
An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors
Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimizat…
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid Tumors
Estimated
~$10 – $8,750
Novartis PharmaceuticalsNCT06726148